Novel insights into to the biology of Fabry disease


A team from Normandie University in Rouen used the Olink® Explore 1536 high-throughput platform for protein biomarker discovery to gain much-needed new insights into the biology of Fabry disease (FD), a rare,  X-linked lysosomal disease. Although it is caused by a deficiency of α-galactosidase A activity, the systemic effects leading to the observed phenotypes of FD remain only partially understood. Here they used proteomics to gain more insights into the biology underlying the disease, as well as to look for new diagnostic markers.


Primary analysis showed that 615 proteins were differentially expressed in FD v controls, with 365 of these being completely novel findings. The FD associations of several of the key proteins identified were corroborated with ELISAs, (e.g., STIP1, FGF2, and IL7). Pathway analysis of the proteins identified implicated remodeling of several key processes in FD, including cytokine-mediated pathways, extracellular matrix, and the vacuolar/lysosomal proteome. These changes in plasma proteomics are indicative of a tissue-wide metabolic remodeling in FD.

Further network strategies and application of machine learning to look at patient-specific tissue metabolic remodeling was then able to describe a robust predictive consensus protein signature for FD. 17 proteins (CD200, SPINT1, CD34, FGFR2, GRN, ERBB4, AXL, ADAM15, PTPRM, IL13RA1, NBL1, NOTCH1, VASN, ROR1, AMBP, CCN3, and HAVCR2) were used to derive multiple predictive models, most of which had high accuracies, with AUCs >0.9. The the most predictive model (PTPRM, HAVCR2, CD200, IL13RA1,SPINT1, CD34, and CCN3) showed an AUC = 0.966 to predict FD. The authors concluded that their results will facilitate further studies to understand the molecular mechanisms in FD to pave the way for better diagnostics and therapeutics.



Tebani A, Barbey F, Dormond O, et al. Deep next-generation proteomics and network analysis reveal systemic and tissue-specific patterns in Fabry disease. (2023) Translational Research, DOI: 10.1016/j.trsl.2023.02.006

This large-scale plasma proteomics profiling enabled us to explore the broad metabolic rewiring underlying FD. We described a comprehensive and deep protein profiling coupled with systems-based strategies to parse the biological plasticity in FD to inform clinical heterogeneity and biological individuality and, ultimately, pave the way to precision medicine

Tebani et al. (2023)

Peer-reviewed publications citing the use of Olink panels

Olink’s Proximity Extension Assay (PEA) technology has been used for protein biomarker discovery and analysis across a very broad range of disease areas and applications, providing actionable insights into disease biology and helping to drive future development of new and better therapeutics. There are now well over 1000 publications citing the use of our assays and the list is growing rapidly. Please visit our library of publications to see some of the extraordinary work produced by Olink customers.

Related Olink Panels